Foxy methoxy is a street name for 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT), a synthetic psychedelic drug in the tryptamine family. It first appeared on the illicit market around 1999 and quickly drew attention from both users and poison control centers for producing intense hallucinogenic effects alongside a worrying pattern of medical emergencies, including at least two documented deaths. The drug acts primarily on serotonin systems in the brain, but its pharmacology is more complex than that of many better-known psychedelics, and its risks are poorly understood by most people who encounter it.
Where Foxy Methoxy Came From
5-MeO-DIPT was originally synthesized by the chemist Alexander Shulgin and described in his 1997 book TiHKAL, a catalogue of tryptamine compounds. It remained a laboratory curiosity until 1999, when it began circulating as a recreational drug under the names “Foxy” and “Foxy Methoxy.” By February 2003, the U.S. Drug Enforcement Administration had recorded law enforcement seizures or abuse reports in 12 states. During roughly the same period, the American Association of Poison Control Centers logged 41 exposures, with 26 producing moderate or major health effects.1PubMed Central. Foxy methoxy: a new drug of abuse The drug was placed into Schedule I of the U.S. Controlled Substances Act in 2004, making it illegal to manufacture, possess, or distribute. Many other countries followed with similar prohibitions.
How It Works in the Brain
Foxy methoxy’s psychedelic effects come from its interaction with serotonin receptors, particularly the 5-HT2A receptor, the same target responsible for the hallucinogenic effects of LSD and psilocybin. In animal studies, stimulating this receptor triggers a characteristic head-twitch response that researchers use as a proxy for hallucinogenic activity in humans.2PubMed Central. Neurotoxic Effects of 5-MeO-DIPT: A Psychoactive Tryptamine Derivative in Rats The drug also binds to 5-HT1A and 5-HT2C receptors, though its affinity profile differs depending on the receptor type. One study found that 5-MeO-DIPT had its highest affinity for the 5-HT1A receptor compared to 5-HT2A and 5-HT2C.3PubMed. Hallucinogen-like actions of 5-methoxy-N,N-diisopropyltryptamine in mice and rats A separate structure-activity analysis, however, found that compounds with isopropyl groups (including 5-MeO-DIPT) showed relatively lower affinity at 5-HT1A compared to other tryptamines in the series.4PubMed Central. Structure-activity relationships of serotonergic 5-MeO-DMT derivatives: insights into psychoactive and thermoregulatory properties The discrepancy likely reflects differences in experimental setup, but it underscores that the pharmacology of this drug is still not nailed down as precisely as researchers would like.
Beyond receptor binding, foxy methoxy powerfully blocks the serotonin transporter, the protein that normally pulls serotonin back out of the synapse after it has been released. Laboratory experiments using cells engineered to express this transporter found that 5-MeO-DIPT inhibited serotonin reuptake at concentrations comparable to those effective for cocaine, and it was highly selective for the serotonin transporter over the dopamine and norepinephrine transporters.5PubMed. 5-Methoxy-N,N-diisopropyltryptamine (Foxy), a selective and high affinity inhibitor of serotonin transporter This dual action, simultaneously activating serotonin receptors and blocking serotonin reuptake, sets foxy methoxy apart from “classic” psychedelics like LSD, which primarily stimulate receptors without strongly inhibiting the transporter. The transporter blockade floods the synapse with extra serotonin, amplifying the drug’s effects and raising the ceiling for serotonin-related toxicity.
Rat studies show the drug also boosts dopamine and glutamate levels in several brain regions, including the striatum, nucleus accumbens, and frontal cortex.6PubMed Central. Neurotoxic Effects of 5-MeO-DIPT: A Psychoactive Tryptamine Derivative in Rats Dopamine release likely contributes to the euphoria some users report, while glutamate, the brain’s main excitatory chemical, may help explain the intensity and unpredictability of the experience.
What the Experience Looks Like
User accounts typically describe visual and auditory distortions, euphoria, altered perception of time, and a strong body sensation that can range from pleasant warmth to uncomfortable tension. Doses in the range sometimes cited online hover around 6 to 20 milligrams taken orally, with onset at roughly 20 to 30 minutes and peak effects lasting a few hours. Unlike many tryptamines, foxy methoxy is frequently described as having a pronounced physical or “tactile” component, which some users find appealing but others find disconcerting. Nausea, muscle tension, jaw clenching, and gastrointestinal discomfort are commonly reported side effects even at doses users consider recreational.
The problem is that the margin between a dose someone considers recreational and one that produces a medical emergency is not well defined. Individual variation in metabolism (discussed below) can dramatically shift how much of the active drug reaches the brain, meaning two people taking the same pill can have vastly different experiences.
Acute Toxicity and Medical Emergencies
Hospital case reports paint a picture of a drug that can rapidly produce a dangerous constellation of symptoms. One well-documented case involved a young man who arrived at an emergency department with hallucinations, high blood pressure, rapid heart rate, dilated pupils, and catalepsy, a state of rigid immobility. His symptoms resolved within two hours after treatment with the benzodiazepine lorazepam.7PubMed Central. Foxy methoxy: a new drug of abuse That relatively rapid resolution might make the drug sound manageable, but not all cases go so smoothly.
A separate case report described a patient who developed rhabdomyolysis, the breakdown of muscle tissue that releases proteins into the bloodstream and can damage the kidneys. That patient developed acute kidney failure and required aggressive intravenous fluids and alkaline diuresis before kidney function improved.8Mayo Clinic Proceedings. Rhabdomyolysis and Acute Renal Failure Associated With the Ingestion of Foxy Methoxy Rhabdomyolysis is a known complication of serotonergic overstimulation and hyperthermia, both of which foxy methoxy can cause.
At least two fatal cases have been documented in the forensic literature. In one, a toxicology analysis identified 5-MeO-DIPT along with its two main metabolites in both blood and urine at levels higher than any previously published data for the drug.9PubMed. A fatal poisoning with 5-methoxy-N,N-diisopropyltryptamine, Foxy A second fatal case involved the combination of foxy methoxy and cocaine, with toxicology revealing high concentrations of both substances.10Canadian Society of Forensic Science Journal. A Fatality Involving 5-Methoxy-N, N-Diisopropyltryptamine (“Foxy”) and Cocaine Polydrug use dramatically increases the unpredictability of the outcome, particularly when stimulants and serotonergic drugs are combined.
Why Metabolism Creates a Wild Card
Once swallowed, foxy methoxy is processed by liver enzymes into two main metabolites. One pathway strips the methoxy group off the molecule (O-demethylation), producing 5-OH-DIPT. The other pathway removes one of the isopropyl side chains (N-deisopropylation), producing 5-MeO-IPT. In human liver tissue, a single enzyme, CYP2D6, handles the O-demethylation step, while CYP1A2, CYP2C8, and CYP3A4 share responsibility for the N-deisopropylation step.11PubMed. Oxidative metabolism of 5-methoxy-N,N-diisopropyltryptamine (Foxy) by human liver microsomes and recombinant cytochrome P450 enzymes
The CYP2D6 dependence is the key safety concern here. CYP2D6 is one of the most genetically variable drug-metabolizing enzymes in humans. Roughly 5 to 10 percent of people of European descent carry gene variants that make them “poor metabolizers,” meaning the enzyme works slowly or not at all. At the other end, some people carry extra copies of the gene and are “ultra-rapid metabolizers.” Because CYP2D6 controls one of the two main breakdown routes for foxy methoxy, someone with low CYP2D6 activity may process the drug more slowly, potentially allowing higher blood concentrations to build up. Any other drug or supplement that inhibits CYP2D6, including common medications like certain antidepressants, can create the same bottleneck in anyone.
Rat liver studies show a broadly similar metabolic scheme, with species-specific enzymes filling the equivalent roles, confirming that the two-pathway pattern is not a quirk of one model system.12PubMed. Oxidation of 5-methoxy-N,N-diisopropyltryptamine in rat liver microsomes and recombinant cytochrome P450 enzymes
The Danger of Combining It With MAO Inhibitors
Monoamine oxidase (MAO) is an enzyme that breaks down serotonin, dopamine, and norepinephrine. Drugs that block MAO, called MAO inhibitors, are used as antidepressants but also appear in certain plant preparations like ayahuasca. When a MAO inhibitor is combined with a drug that floods the brain with serotonin, the result can be a catastrophic surge of serotonin activity known as serotonin syndrome, which can be fatal.
Research on a closely related tryptamine, 5-MeO-DMT, showed that co-administering the MAO inhibitor harmaline with even a normally inactive dose of the tryptamine produced extreme hyperactivity in mice, an effect that was blocked by serotonin receptor antagonists.13PubMed Central. Modification of 5-methoxy-N,N-dimethyltryptamine-induced hyperactivity by monoamine oxidase A inhibitor harmaline in mice and the underlying serotonergic mechanisms While that study used 5-MeO-DMT rather than 5-MeO-DIPT, the structural and pharmacological similarities between the two compounds make it reasonable to expect that the same dangerous interaction applies. Because foxy methoxy already blocks the serotonin transporter on its own, adding a MAO inhibitor on top would remove a second layer of serotonin clearance, pushing the risk of serotonin toxicity even higher.
Evidence of Long-Term Brain Damage
One of the most concerning findings to emerge from animal research is that foxy methoxy appears to cause lasting damage to DNA in brain cells. Rats given the drug at various doses showed single-strand and double-strand DNA breaks in cortical tissue, and these breaks were still detectable 60 days after the drug was administered. The drug also increased serotonin levels in brain tissue while decreasing levels of serotonin’s main breakdown product, a pattern consistent with the transporter blockade seen in the in vitro studies.14PubMed Central. Neurotoxic Effects of 5-MeO-DIPT: A Psychoactive Tryptamine Derivative in Rats
Separate cell culture experiments exposed human-derived neuronal cells (SH-SY5Y) and liver cells (Hep G2) to 5-MeO-DIPT. Both cell types showed a dose-dependent drop in viability. At the highest concentration tested, survival of the neuronal cells dropped to about 15 percent of control values, while liver cells dropped to about 11 percent.15SpringerOpen. Effects of exposure to 5-MeO-DIPT during adolescence on brain neurotransmission and neurotoxicity in adult rats The concentrations used in those cell studies were higher than what would typically be seen in a living person after a single recreational dose, so they should be interpreted cautiously. Still, the combined picture from animal and cell studies suggests that foxy methoxy has a genuinely neurotoxic profile, not merely a pharmacologically intense one. The persistence of DNA damage two months after a single exposure in rats is a finding that researchers in the field take seriously, because DNA breaks in neurons, cells that largely do not regenerate, can have irreversible consequences.
How Forensic Labs Detect Foxy Methoxy
Because foxy methoxy is a Schedule I controlled substance and has been implicated in deaths, forensic toxicologists have developed increasingly sensitive methods to detect it and its metabolites. A urine-based method using gas chromatography paired with high-resolution mass spectrometry can identify both the parent drug and its two metabolites, 5-OH-DIPT and 5-MeO-IPT, in the urine of people who have used the drug, with a detection limit of 1 nanogram per milliliter.16Journal of Analytical Toxicology. Determination of 5-MeO-DIPT in Human Urine Using Gas Chromatography Coupled with High-Resolution Orbitrap Mass Spectrometry
Hair analysis provides a longer detection window. A validated method using liquid chromatography and tandem mass spectrometry achieved a detection limit of 0.05 picograms per milligram of hair, making it possible to document use weeks or months after the fact.17PubMed. Application of hair analysis to document illegal 5-methoxy-N,N-dissopropyltrptamine (5-MeO-DiPT) use The development of these analytical tools is part of a broader push in forensic toxicology. Between 2015 and 2020, at least 22 new methods were published for identifying tryptamines and their metabolites in biological samples, with liquid chromatography-mass spectrometry being the dominant platform.18PubMed Central. Toxicology and Analysis of Psychoactive Tryptamines The practical upshot is that foxy methoxy use is increasingly traceable, whether in emergency department toxicology screens, workplace testing, or postmortem investigations.
How Foxy Methoxy Compares to Better-Known Psychedelics
People sometimes assume that tryptamine psychedelics are roughly interchangeable in their risk profile, but foxy methoxy departs from the classic tryptamine pattern in ways that matter. Psilocybin and LSD primarily activate serotonin receptors without strongly blocking the serotonin transporter. That distinction matters because transporter blockade floods the synapse from the reuptake side, creating a different and arguably more dangerous pharmacological situation, especially when combined with anything else that raises serotonin. The potency of foxy methoxy’s transporter inhibition, comparable to cocaine’s, is not something you see with psilocybin.19PubMed. 5-Methoxy-N,N-diisopropyltryptamine (Foxy), a selective and high affinity inhibitor of serotonin transporter
The neurotoxicity evidence also sets it apart. Classic psychedelics like psilocybin have not been shown to produce lasting DNA damage in animal models at typical dose ranges. Foxy methoxy, by contrast, left measurable DNA breaks in rat brain tissue that persisted for months.20PubMed Central. Neurotoxic Effects of 5-MeO-DIPT: A Psychoactive Tryptamine Derivative in Rats Researchers suspect that the combination of transporter blockade, receptor activation, and glutamate release creates an oxidative stress environment that damages cellular DNA, but the exact chain of events is still being worked out.
It is also worth noting that foxy methoxy’s CYP2D6-dependent metabolism creates a pharmacokinetic unpredictability that better-studied psychedelics largely avoid. Psilocybin, for example, is converted to psilocin mainly by alkaline phosphatase, an enzyme with far less genetic variability across the population. With foxy methoxy, two people sitting next to each other taking the same dose can end up with meaningfully different blood levels based on which CYP2D6 gene variants they carry, a lottery nobody wins by guessing.
Why Research Remains Thin
Despite the documented fatalities and the troubling neurotoxicity data, foxy methoxy has received far less research attention than drugs like MDMA, LSD, or psilocybin. Its Schedule I status makes it difficult for researchers to obtain and study. Its relative rarity on the drug market means there is less clinical urgency driving funding compared to, say, fentanyl or methamphetamine. Most of what is known comes from a handful of preclinical pharmacology papers, forensic case reports, and a few cell culture studies. There are no controlled human studies of any kind, meaning that everything we know about its effects in people comes from emergency department visits, poison control data, and self-reported experiences online.
That gap matters for a practical reason. When someone shows up to an emergency department after taking foxy methoxy, clinicians are working mostly from general serotonin toxicity protocols rather than drug-specific guidelines. Benzodiazepines for agitation, intravenous fluids, cooling measures for hyperthermia, and supportive care for any organ damage that develops are the standard approach, the same playbook used for serotonin syndrome from any cause.21PubMed Central. Foxy methoxy: a new drug of abuse There is no antidote, no established dose-response curve for toxicity, and no way for an emergency physician to reliably predict from an ingested dose whether a patient is heading for a mild scare or rhabdomyolysis and kidney failure.